	US 11,957,744 B2
	Monovalent vaccine formulation and a method for preparation thereof
Guruswamy Prabhakaran, Bedong (MY); Manickam Ravichandran, Bedong (MY); Kurunathan A/L Sinniah, Bedong (MY); and Yean Yean Chan, Penang (MY)
Assigned to AIMST UNIVERSITY, Bedong (MY)
Appl. No. 16/960,865
Filed by AIMST UNIVERSITY, Bedong Kedah (MY)
PCT Filed Dec. 26, 2018, PCT No. PCT/MY2018/050098 § 371(c)(1), (2) Date Jul. 8, 2020, PCT Pub. No. WO2019/139468, PCT Pub. Date Jul. 18, 2019.
Claims priority of application No. PI 2018700106 (MY), filed on Jan. 9, 2018.
Prior Publication US 2022/0175905 A1, Jun. 9, 2022
Int. Cl. A01N 63/00 (2020.01); A61K 39/02 (2006.01); A61P 31/04 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/107 (2013.01) [A61P 31/04 (2018.01); A61K 2039/522 (2013.01)]

5 Claims

1. A monovalent vaccine formulation against Vibrio cholerae O139 comprising:

a live attenuated cholera vaccine strain;

a vaccine medium having starch, cellulose, dextrose, and yeast extract; and

a phosphate buffer saline;

wherein the strain is VCUSM14P and wherein the vaccine medium comprising starch (3.25-6.75%), cellulose (2.50-4%), dextrose (18.25-24.50%), yeast extract (0.01-0.05%), and NaCl (0.05-0.15%).